Oregon Therapeutics & Lantern Pharma Collaborate To Optimize Cancer Drug

 


Lantern Pharma Inc. (NASDAQ: LTRN) partners with Oregon Therapeutics to advance the development of XCE853, a pioneering PDI inhibitor, across various cancer types. Leveraging Lantern's RADR® AI platform, the collaboration aims to identify biomarkers and efficacy signatures, crucial for precision development and patient selection. This strategic alliance seeks to address the complexities associated with PDI inhibitors, offering a promising pathway to enhance cancer treatment strategies.

Oregon Therapeutics' CEO, Marc-Henry PITTY, underscores XCE853's preclinical efficacy and the potential for targeted development across multiple cancers. Through comprehensive molecular analysis powered by RADR®, the collaboration intends to uncover new insights into XCE853's therapeutic potential and its application in additional cancer indications. Panna Sharma, CEO of Lantern Pharma, emphasizes RADR®'s role in navigating the complexities of drug development, enabling informed decisions crucial for advancing XCE853 towards clinical success. With equal IP co-ownership, this collaboration marks a significant step towards pioneering AI-driven solutions in cancer therapeutics.

Read More - https://www.techdogs.com/tech-news/business-wire/oregon-therapeutics-lantern-pharma-launch-strategic-ai-collaboration-to-optimize-development-of-first-in-class-drug-candidate-xce853-a-potent-inhibitor-of-cancer-metabolism

Comments

Popular posts from this blog

Top 5 Product Lifecycle Management Software Of 2025

Orlagh Neary, Former VP Of Quantum Ecosystem Engagement And GTM At Microsoft On Building Scalable And Safe AI And Quantum

Softchoice Announces Launch Of Cloud Cost Optimization